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We evaluated the cost-effectiveness of two alternative direct-acting antiviral (DAA) treatment policies in a real-life cohort of
hepatitis C virus–infected patients: policy 1, “universal,” treat all patients, regardless of ﬁbrosis stage; policy 2, treat only
“prioritized” patients, delay treatment of the remaining patients until reaching stage F3. A liver disease progression Markov
model, which used a lifetime horizon and health care system perspective, was applied to the PITER cohort (representative of
Italian hepatitis C virus–infected patients in care). Speciﬁcally, 8,125 patients naive to DAA treatment, without clinical, soci-
odemographic, or insurance restrictions, were used to evaluate the policies’ cost-effectiveness. The patients’ age and ﬁbrosis
stage, assumed DAA treatment cost of e15,000/patient, and the Italian liver disease costs were used to evaluate quality-
adjusted life-years (QALY) and incremental cost-effectiveness ratios (ICER) of policy 1 versus policy 2. To generalize the
results, a European scenario analysis was performed, resampling the study population, using the mean European country-
speciﬁc health states costs and mean treatment cost of e30,000. For the Italian base-case analysis, the cost-effective ICER
obtained using policy 1 was e8,775/QALY. ICERs remained cost-effective in 94%-97% of the 10,000 probabilistic simula-
tions. For the European treatment scenario the ICER obtained using policy 1 was e19,541.75/QALY. ICER was sensitive to
variations in DAA costs, in the utility value of patients in ﬁbrosis stages F0-F3 post–sustained virological response, and in the
transition probabilities from F0 to F3. The ICERs decrease with decreasing DAA prices, becoming cost-saving for the base
price (e15,000) discounts of at least 75% applied in patients with F0-F2 ﬁbrosis. Conclusion: Extending hepatitis C virus treat-
ment to patients in any ﬁbrosis stage improves health outcomes and is cost-effective; cost-effectiveness signiﬁcantly increases
when lowering treatment prices in early ﬁbrosis stages. (HEPATOLOGY 2017;66:1814-1825)
Hepatitis C virus (HCV) chronic infection is aworldwide public health concern because itis one of the leading causes of cirrhosis,
hepatocellular carcinoma (HCC), and liver transplan-
tations worldwide. An estimated 71 million people
have chronic hepatitis C infection, and a signiﬁcant
number of those who are chronically infected will
develop cirrhosis or liver cancer. Approximately
399,000 people die each year from hepatitis C, mostly
from cirrhosis and HCC.(1,2)
Although the overall prevalence of HCV infection has
been declining and the incidence has dropped signiﬁ-
cantly since peaking in 1989, the total health care costs
for treating infected individuals have continued to rise.(3)
Abbreviations: DAA, direct-acting antiviral; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; ICER, incremental cost-effectiveness ratio;
IFN, interferon; QALY, quality-adjusted life-years; SVR, sustained virological response; WTP, willingness to pay.
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Given the enormous health loss attributable to viral hepa-
titis and the availability of effective treatment, there exists
a great opportunity to drastically improve public health.(4)
The development of direct-acting antiviral agents
(DAAs) represents a historical breakthrough, in that their
use can eradicate HCV in >95% of infected individuals,
preventing chronic liver disease from developing into cir-
rhosis and HCC.(5-7) In light of this, arresting or pre-
venting the onset of severe liver disease has become a
reality and thus a critical focus of treatment. However,
enthusiasm for the new drugs has been dampened by the
initially exorbitant price and the great number of persons
who would need these drugs, making their sustained use
unfeasible for health care systems, particularly in
resource-constrained countries. This has given rise to a
heated debate as to how to best prioritize patients for
treatment, yet the optimal timing of treatment and the
real-life added health beneﬁts and costs of early treatment
remain unknown.(8,9) Since 2015, DAA treatment has
been recommended for patients with chronic HCV liver
disease, with the exception of those with a short life
expectancy not related to liver disease.(10,11) However,
currently, most insurers cover therapy only in the
advanced stages of ﬁbrosis.
Given that a “life without HCV” is now an attain-
able goal, it is crucial that health policies that include
the cost-effectiveness of access to treatment for
patients with chronic HCV in care be developed. To
this end, we evaluated the health gains and costs of
two strategies that differed in terms of the start times
of DAA interferon (IFN)–free regimens. The evalua-
tion was performed using a lifetime multicohort
model of real-life patients with chronic HCV infec-
tion considered to be representative of patients in
care.(12)
Patients and Methods
SCENARIOS OF TREATMENT
POLICY
Two scenarios of policies for DAA IFN-free regi-
mens were simulated and compared:
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1. Policy 1: “universal,” treat all patients, indepen-
dently of the fibrosis stage
2. Policy 2: treat only “prioritized” patients and delay
treatment of the remaining patients until reaching
fibrosis stage F3
A description of the data-source analysis and model-
ing, in addition to that provided below, can be found
in the Supporting Information.
STUDY DESIGN
The analysis followed two steps: we ﬁrst computed
the cost-effectiveness ratio associated with the popula-
tion of PITER,(12) then applied a resampling proce-
dure to generalize the PITER Italian population to
different European countries. We associated to this
population the average costs of disease stages of ﬁve
European countries to obtain an incremental cost-
effectiveness ratio (ICER) that is representative of a
European context.
STUDY POPULATION
The ongoing Italian HCV cohort (PITER) of 8,125
consecutive patients undergoing care for chronic HCV
infection in approximately 100 public clinical centers
in the period from May 2014 to December 2015 was
considered (Supporting Tables S2 and S3).(12)
MODEL STRUCTURE
Lifetime HCV disease progression during the natu-
ral history of chronic infection and the related costs
were evaluated using an adapted multicohort Markov
model in a lifetime horizon and health care system per-
spective (Fig. 1).(13,14) Patients entered the model at
the proper age and ﬁbrosis stage (i.e., stages F0, F1/2,
F3, and F4 or in the stages of decompensated cirrhosis
and/or HCC), and they were followed inside the
model over a lifetime. The model inputs are shown in
Tables 1 and 2.(15-18)
TRANSITION PROBABILITIES
Progression of HCV liver disease was considered as
an increase in the severity of liver ﬁbrosis (from F0 to
F4 according to the Metavir classiﬁcation). In the
base-case analysis, the transition probabilities from
ﬁbrosis stages F0 to F4 was assumed to be linear over
time, following a constant annual progression rate.
Patients could remain in their current stage or
deteriorate; possible regression of liver ﬁbrosis follow-
ing viral eradication was not taken into consideration.
Patients who did not reach a sustained virological
response (SVR) were assumed to have proceeded
through the natural history of liver disease and to have
not been retreated. Patients with mild ﬁbrosis who
achieved SVR were considered to have had no risk of
further liver disease progression; the reinfection rate
was not considered. It was possible for patients with
cirrhosis to progress to decompensated cirrhosis or
HCC, which were considered in the model to be
mutually exclusive. The stage of decompensated cir-
rhosis or HCC could have led to the patient’s being
selected for an orthotopic liver transplantation. Given
that transplant costs are relatively high, the model
envisaged two separate statuses: one for the ﬁrst year
after the transplant and one for the successive years.
Finally, patients in these two stages could have pro-
gressed toward death. Each patient was assumed to
have progressed annually through the various stages of
ﬁbrosis according to the natural disease progression
rate, considering also the SVR, for the two HCV treat-
ment scenarios. Based on the transition probabilities,
each patient could follow one of three different paths
in each life-year cycle: (1) continue in the same health
without suffering from any event, (2) have a liver-
related event, or (3) die of a liver-related cause (Fig. 1).
In patients with cirrhosis, the residual risks for HCC
and slower disease progression compared to patients
who achieved SVR prior to reaching cirrhosis were
considered.(19-22) In patients who achieved SVR in the
cirrhosis stage, the residual risks for HCC and slower
disease progression compared to patients who achieved
SVR prior to reaching cirrhosis were calculated using
the disease progression based on the SVR ratios
reported for patients with a ﬁbrosis stage higher than
F3 (Tables 1 and 2). The transition probabilities for
patients who achieved SVR in the stage of decompen-
sated cirrhosis or HCC were assumed to be the same
as in patients who did not achieve SVR. Although
these assumptions are potential limitations of the
study, they are conservative as they are actually detri-
mental to the policy under consideration.
In the sensitivity analysis, transition probabilities
and nonliver mortality rates were assumed to follow a
nonlinear progression. To model this assumption, an
exponential distribution was associated with each tran-
sition probability.
Patients coinfected with human immunodeﬁciency
virus (3% of the cohort) were considered to have had
the same HCV transition probabilities as the HCV
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monoinfected patients; this assumption would not
have affected the results, given that the coinfected
patients were included in the planning strategies in the
same way (i.e., prioritized independently of the ﬁbrosis
stage).
EFFICACY: SVR RATES
IFN-free HCV regimens of second-generation
DAAs, approved by the US Food and Drug Adminis-
tration and the European Medicines Agency, were
considered. The likelihood of an SVR was deﬁned in
accordance with the SVR rates of IFN-free treatment
regimens, recommended as preferred or alternative
treatments for each HCV genotype (stratiﬁed by pres-
ence or absence of cirrhosis) in the guidelines of the
European Association for the Study of the Liver and
the American Association for the Study of Liver Dis-
eases and validated by expert clinicians.(10,11) The SVR
and the standard errors used in the base-case analysis
and the sensitivity analysis, respectively, are reported in
Supporting Tables S5-S9.
COST OF HCV HEALTH STATES
The use of health care resources was based on the
actual disease status of real-life patients entered in the
model. Annual health care costs were associated with
their respective disease status. The cost of the resources
related to each HCV health state, used for the imple-
mentation of the model, was quantiﬁed from the per-
spective of the Italian National Health Service by the
permanent members of the Workshop of Economics
and Drugs in Hepatology, as reported.(23) Unit costs
were valorized using the Italian National Health Ser-
vice inpatient and outpatient reimbursement tariffs.
Speciﬁcally, the model accounted for costs of HCV
genotyping, ﬁbrosis staging, and therapy monitoring,
including visits, blood liver tests, and HCV RNA
quantiﬁcation. These costs were determined using the
Medicare reimbursement schedule and published
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FIG. 1. Markov model of progression of HCV-related liver disease. Potential outcomes of chronic liver disease progression are
deﬁned as speciﬁc health states reported in each of the boxes. In the Markov chain, each real-life patient moves through states as indi-
cated by the arrows. The arrow indicates the transition from one state to the other according to the natural history of chronic liver dis-
ease. Speciﬁcally, in this Markov modeling process for patients with cirrhosis, it was possible to progress to four stages: three stages of
decompensated cirrhosis (i.e., encephalopathy, ascites, or variceal bleeding) and HCC, which were considered in the model to be
mutually exclusive.
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literature. The frequency of monitoring visits and tests
was based on HCV treatment guidelines and clinical
judgment. The costs of outpatient specialist visits and
diagnostic tests were estimated according to the
national medical care payment databases (national tar-
iffs) deﬁned by the list of charges for specialist medical
and outpatient services, as updated by the Italian Min-
istry of Health in October 2012. The Diagnosis
Related Group system currently in use was applied as a
proxy for the costs of hospitalization due to decompen-
sated cirrhosis and HCC.(14)
The annual discount rate applied to costs was 3%.
The costs and the sources of the data on costs used in
the analysis are reported in the Supporting Informa-
tion. The costs of IFN-free treatments currently vary
by country and are negotiated with speciﬁc discount
policies. The base-case analysis was carried out under
the hypothetical price of e15,000 per patient, consider-
ing this to be the mean cumulative price of a 12-week
IFN-free DAA regimen negotiated in Italy (Support-
ing Table S11).
MODEL OUTCOMES
The outcomes of the model are expressed in terms
of quality-adjusted life-years (QALYs). The rationale
for choosing the cost utility for the cost-effectiveness
analysis was that this analysis was not designed to
compare the effectiveness of two different drug
combinations but instead to evaluate two scenarios of
the same treatment, which strongly impacts quality of
life, as well as years of life gained. The utilities used are
reported in Supporting Tables S13 and S14. Health
beneﬁts were discounted by 3%. The utility value of
patients in ﬁbrosis stages F0-F3 post-SVR was
TABLE 1. Disease Progression Rates in Patients Who Reach SVR
Stage Value (SE) Distribution Alpha Beta Source
F0 to F1/2 0.00 Beta 14.79 127.40 No progression assumed
F1/2 to F3 0.00 Beta 0.52 16.67 No progression assumed
F3 to F4 0.00 Beta 1.74 15.63 No progression assumed
F4 to DC (HE) 0.001 (0.00045) Beta 8.70 281.30 (15,16) according to the SVRs reported in (11)*
F4 to DC (VB) 0.001 (0.00045) Beta 8.70 281.30 (15,16) according to the SVRs reported in (11)*
F4 to DC (AS) 0.001 (0.00045) Beta 8.70 281.30 (15,16) according to the SVRs reported in (11)*
F4 to HCC 0.010 (0.0075) Beta 0.98 97.02 (15,16) according to the SVRs reported in (11)*
DC (HE) to HCC 0.013 (0.01) Beta 89.90 809.10 (15) according to the SVRs reported in (11)*
DC (HE) to LT 0.015 (0.01) Beta 107.58 870.42 (15) according to the SVRs reported in (11)*
DC (HE) to death 0.012 (0.01) Beta 73.62 744.38 (15) according to the SVRs reported in (11)*
DC (VB) to HCC 0.013 (0.01) Beta 89.90 809.10 (15) according to the SVRs reported in (11)*
DC (VB) to LT 0.015 (0.01) Beta 107.58 870.42 (15) according to the SVRs reported in (11)*
DC (VB) to death 0.012 (0.01) Beta 73.62 744.38 (15) according to the SVRs reported in (11)*
DC (AS) to HCC 0.013 (0.01) Beta 89.90 809.10 (15) according to the SVRs reported in (11)*
DC (AS) to LT 0.015 (0.01) Beta 107.58 870.42 (15) according to the SVRs reported in (11)*
DC (AS) to death 0.012 (0.01) Beta 73.62 744.38 (15) according to the SVRs reported in (11)*
HCC to LT year 1 0.20 (0.01) Beta 319.80 1,279.20 (17)
HCC to death 0.43 (0.01) Beta 1,053.50 1,396.50 (17)
LT, year 1 to death 0.15 (0.01) Beta 191.10 1,082.90 (17)
LT, post to death 0.057 (0.01) Beta 30.58 505.93 (17)
*The respective references used are reported in Supporting Tables S6 and S7.
Abbreviations: AS, ascites; DC, decompensated cirrhosis; HE, hepatic encephalopathy; LT, liver transplantation; VB, variceal
bleeding.
TABLE 2. Disease Progression Rates in Patients Without
SVR
Stage Value (SE) Distribution Alpha Beta Source
F0 to F1/2 0.10 (0.03) Beta 14.79 127.40 (18)
F1/2 to F3 0.03 (0.04) Beta 0.52 16.67 (17)
F3 to F4 0.10 (0.07) Beta 1.74 15.63 (15)
F4 to DC (HE) 0.03 (0.01) Beta 8.70 281.30 (15)
F4 to DC (VB) 0.03 (0.01) Beta 8.70 281.30 (15)
F4 to DC (AS) 0.03 (0.01) Beta 8.70 281.30 (15)
F4 to HCC 0.05 (0.01) Beta 23.70 450.30 (15)
DC (HE) to HCC 0.10 (0.01) Beta 89.90 809.10 (15)
DC (HE) to LT 0.11 (0.01) Beta 107.58 870.42 (15)
DC(HE) to death 0.09 (0.01) Beta 73.62 744.38 (15)
DC (VB) to HCC 0.10 (0.01) Beta 89.90 809.10 (15)
DC (VB) to LT 0.11 (0.01) Beta 107.58 870.42 (15)
DC (VB) to death 0.09 (0.01) Beta 73.62 744.38 (15)
DC (AS) to HCC 0.10 (0.01) Beta 89.90 809.10 (15)
DC (AS) to LT 0.11 (0.01) Beta 107.58 870.42 (15)
DC (AS) to death 0.09 (0.01) Beta 73.62 744.38 (15)
HCC to LT Year 1 0.20 (0.01) Beta 319.80 1,279.20 (17)
HCC to death 0.43 (0.01) Beta 1,053.50 1,396.50 (17)
LT, year 1 to death 0.15 (0.01) Beta 191.10 1082.90 (17)
LT, post to death 0.057 (0.01) Beta 30.58 505.93 (17)
Abbreviations: AS, ascites; DC, decompensated cirrhosis; HE,
hepatic encephalopathy; LT, liver transplantation; VB, variceal
bleeding.
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assumed to be 1, presuming a state of full health after
SVR. No changes in utility values were considered for
the other ﬁbrosis stages (>F3), even if after SVR in
the base-case analysis. In the sensitivity analysis the
utilities were varied according to a beta variable in
order to take into account potential variability in
national quality of life values. In the base-case analysis
we assumed that the mortality rate of people affected
by chronic HCV infection in stages F0-F3 coincided
with the mortality rate of the general population (Sup-
porting Table S4).
INCREMENTAL COST-
EFFECTIVENESS ANALYSIS
The model produces discounted lifetime QALYs
and direct medical costs for each treatment policy. The
ICER was calculated as the ratio of the difference in
costs over the differences in QALYs between the two
policies. We tested whether policy 1 compared to pol-
icy 2 produced an ICER below the willingness to pay
(WTP) threshold generally taken into account by the
National Institute for Clinical Excellence, a UK agency
(i.e., e20,000-40,000/QALY).(24)
MULTIVARIATE SENSITIVITY
ANALYSIS
A sensitivity analysis was conducted to test the
robustness of the study results. The average values and
standard errors were used to derive the scale and shape
of the parameters of each model input (alpha and beta,
Tables 1 and 2). Gamma random variables for cost
drivers and beta random variables for utilities, transi-
tions, and SVR were assumed, which is in accordance
with the methodological guidelines of the International
Society of Pharmacoeconomics and Outcomes
Research.(25) To account for all of the ICER realiza-
tions given the simultaneous variation of each parame-
ter included in the model (transition probabilities,
SVR, and utility), a Monte Carlo analysis with 10,000
simulations was conducted. The distribution of ICERs
obtained in the simulation was presented on a cost-
effectiveness plot showing the incremental costs and
incremental QALYs resulting from each model reali-
zation. Furthermore, the cumulated distribution was
plotted on a cost-effectiveness acceptability curve,
which allows for observation of the probability of the
ICER being under a certain threshold representing the
WTP of a third-party payer for a QALY gained. The
model was constructed using Excel Visual Basic.
RESAMPLING SCENARIO
To generalize the results of our study to different
European contexts, a scenario analysis was performed.
The population was reassembled to take into account
different distributions of populations among ﬁbrosis
levels in different European countries. Resampling was
performed by increasing (or decreasing) the original
population of PITER in each level of ﬁbrosis by using
a uniform random variable ranging from 0 to 1.
In the sensitivity analysis, the transition probabilities
were assumed to follow a nonlinear progression by
associating an exponential variable ranging from 0 to 1
with each transition probability. Moreover, we charac-
terized the transition probabilities using “under stag-
ing” and “over staging” variables. Thus, applying a
further increase of exponential distribution, we
assumed different rates for later disease stages (F3 and
F4) compared to stages F0-F3. We considered also the
diagnostic accuracy of methods to assess ﬁbrosis, in
that a certain proportion of patients with F3 probably
have F4 liver ﬁbrosis which has been underdiagnosed
(and this is true for all methods used to assess ﬁbrosis,
both histological and noninvasive). This uncertainty
was taken into account to model the utility value for
ﬁbrosis stages F0-F3 post-SVR.(26)
In this scenario analysis, the consumption of resour-
ces related to each HCV health state was quantiﬁed
based on updated data that included costs by HCV
health state reported in France, Germany, Italy,
Romania, and the United Kingdom. Average costs of
disease stages were calculated (Supporting Table
S10).(23,27-30)
To take into account higher hypothetical prices
associated with HCV treatment, we included in the
scenario analysis the price variation ranging from
e15,000 to e40,000 (the mean hypothetical European
price considered for the scenario analysis was e30,000).
HCV patient mortality was adjusted using an expo-
nential random distribution to account for its
variability.
We used a tornado graph to illustrate the response
of the European ICER to the variability of each
parameter considered for the scenario analysis.
DECREASING DAA PRICE
SCENARIO
To determine whether policy 1 became dominant
(i.e., less costly and more effective than policy 2), a sce-
nario analysis on decreasing DAA regimen prices was
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also conducted. The minimum price of e15,000 was
assumed to have remained stable for patients in the F3
or F4 stage of liver ﬁbrosis, whereas the price was lower
for patients with mild liver disease, applying two dif-
ferentiated discount levels. Speciﬁcally, the price for
patients in the F0 stage was discounted at a different
rate from that for patients in the F1/F2 stage. Differ-
ent price combinations were simulated, and the sensi-
tivity analysis deﬁned the level of prices in which
policy 1 became dominant.
ETHICS
The protocol of the HCV cohort study was
approved by the ethics committee of the Italian
National Institute of Public Health and by each of the
local ethics committees of the participating clinical
centers.(12)
Results
BASE-CASE ANALYSIS
The median age of the study population was 58
years (range 20-95 years). At the DAA IFN-free price
of e15,000, treating all patients regardless of ﬁbrosis
stage (policy 1) cost e301,788,399 and produced
93,131 QALYs. On the other hand, treating priori-
tized patients ﬁrst and the remaining patients once
they reached the F3 ﬁbrosis stage cost e269,841,561
and produced 89,490 QALYs. Treating all stages of
ﬁbrosis compared with treating only “prioritized”
patients increased costs by e31,946,839, whereas the
incremental QALYs were 3,641. The ICER of policy
1 was e8,775/QALY gained. Policy 1 was therefore
cost-effective compared to the threshold value gener-
ally taken into account by the National Institute for
Clinical Excellence.(24)
MULTIVARIATE PROBABILISTIC
SENSITIVITY ANALYSIS
The results of the Monte Carlo probabilistic analysis
are shown in Fig. 2. Most points on the cost-
effectiveness plot (Fig. 2A) are distributed in the
northeast quadrant, showing that policy 1 was associ-
ated with higher costs and greater beneﬁts than policy
2. The curve in Fig. 2B shows that when treating all
stages of liver disease, ICERs remained below
e30,000/QALY gained in 94% of the simulations
assumed and below e40,000/QALY gained in 97%.
RESAMPLING EUROPEAN
SCENARIO ANALYSIS
The ICER of the European scenario analysis (DAA
mean price e30,000) was e19,541.75/QALY gained.
It was therefore cost-effective compared to the thresh-
old value generally taken into account by the National
Institute for Clinical Excellence.(24) The most sensitive
parameter was the HCV treatment price (Fig. 3). The
ICER varied from e9,107.60/QALY when the DAA
regimen price was e15,000 to e26,497.84/QALY
when the DAA regimen price was e40,000. The
ICER was also sensitive to variations in the utility
value of patients in ﬁbrosis stages F0-F3 post-SVR
and in the transition probabilities from F0-F3, whereas
no impact in ICER was observed for the transition
probabilities from F3 to F4. A slight impact on ICER
was observed for the population in ﬁbrosis stage F1-
F2, whereas ICER was not sensitive to variations in
other variables analyzed (Fig. 3).
DECREASING DAA PRICE
SCENARIO ANALYSIS
Considering variables with the highest impact on
ICER obtained by the sensitivity scenario analysis (i.e.,
DAA price and transition probabilities), 15 different
combinations of price levels differentiated by ﬁbrosis
stage and discount rate (Fig. 4; Supporting Table S15)
were evaluated. The ICERs decrease with decreasing
price levels of the treatment regimens in patients with
F0 ﬁbrosis, until reaching dominance, meaning lower
costs and higher beneﬁts in terms of QALY gained for
policy 1 compared to policy 2. For discounts of the
base price of at least 75% applied in patients with F0-
F2 ﬁbrosis, policy 1 became dominant.
The Monte Carlo analysis, for the DAA regimen
price of e15,000 for patients with ﬁbrosis stage F3 or
higher and e3,750 for patients with ﬁbrosis stage F0-
F2 (75% discount) shows that in 41% of scenarios pol-
icy 1 was dominant and the ICER fell below the
threshold of e30,000/QALY gained in 99.4% of sce-
narios and below e40,000/QALY gained in 99.5% of
scenarios (Supporting Fig. S3).
Discussion
The World Health Organization foresees the elimi-
nation of HCV infection by 2030, through achieving
such global targets as a 65% reduction in HCV-related
deaths and the treatment of 80% of eligible persons
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with chronic HCV infection.(31) In light of this and
the current, nearly worldwide restrictions in DAA
accessibility, we evaluated the costs and beneﬁts of two
scenarios of access to DAAs, populating the Markov
model with a real-life cohort of patients. Because the
cohort can be reasonably considered to be a
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FIG. 2. (A) Cost-effectiveness plot according to Monte Carlo probabilistic sensitivity analysis. The Monte Carlo scenarios (10,000)
were arranged on a cost-effectiveness plot and then reported on a cost-effectiveness acceptability curve. Probabilistic results were
depicted using a cost-effectiveness plane, which consists of a four-quadrant diagram, where the x axis represents the additional total
cost of implementing this outcome and the y axis represents the incremental level of effectiveness of an outcome. Most of the ICERs
(calculated as incremental costs by the incremental QALYs comparing policy 1 to policy 2) reported in the cost-effectiveness plane are
associated with positive incremental health consequences and costs, as in quadrant 1 of the cost-effectiveness plane. (B) Cost-
effectiveness acceptability curve. The results of 10,000 Monte Carlo simulations (probabilistic sensitivity analysis) in which all input
variables are varied simultaneously based on the listed ranges are reported. The graph shows the percentage of simulations in which
policy 1 was considered cost-effective compared with policy 2, depending on the WTP threshold. As the WTP increases (from left to
right on the x axis), the percentage of simulations resulting in the “universal” treatment of all patients being cost-effective also
increases. For example, for treatment at a WTP of e30,000/QALY, treating all patients is cost-effective in 94% of cases; at a WTP of
e 40,000/QALY, treating all patients is cost-effective in 97% of cases.
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FIG. 3. Sensitivity European scenarios. The tornado diagram depicts the results of one-way sensitivity analysis for the inputs that
were varied in the scenario analysis. The vertical line corresponds to all the parameters at their respective base values (mean DAA price
e30,000) and represents the ICER in the base-case analysis (e19,541.75/QALY gained). The horizontal bars represent the variation
of the ICER, given variations of parameters of scenario analysis. The bars to the right of the base-case ICER indicate an increase in
the ICER relative to the base case to the upper limit of the input variable; the bars to the left indicate the inverse. The longest bar
(reﬂecting the parameter generating the major impact) is placed at the top, and the other bars are arrayed in descending order of
length (i.e., when the price increases from e15,000 to e40,000, the ICER increases). The black bars indicate a direct correlation
between the increase in the parameter’s value and the ICER, whereas the gray bars indicate an inverse correlation. The HCV treat-
ment price is the parameter with the greatest effect on the ICER, in that it has the highest range as the absolute value of the differ-
ence between the upper and the lower inputs followed by utility value variations and transition probabilities from F0-F3.
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FIG. 4. Decreasing price scenarios. ICERs were determined for 15 different combinations of price levels differentiated by ﬁbrosis
stage and discount rates and are presented as vertical bars. The ﬁrst column corresponds to the ICER obtained applying the base price
(e15,000). The columns that follow the ﬁrst report each ICER obtained using the discounted DAA regimen costs, as indicated in
percent on the x axis for stages of ﬁbrosis F0 (the ﬁrst percent number) and F1/F2 (the second percent number). ICERs continued to
decrease with decreasing price levels of the treatment regimens in patients with F0 ﬁbrosis, until reaching dominance for discounts of
the base price of at least 75%, applied in patients with F0-F2 ﬁbrosis.
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representative sample of patients in care without any
kind of clinical, sociodemographic, or insurance
restrictions,(12) the only assumptions reﬂected in the
results are those made for the model and not made on
a hypothetical population. The ICERs calculated for
Italy and those obtained in the European DAA treat-
ment scenario have shown an overall cost-effectiveness
below the WTP threshold. The cost of treating this
large population, independently of ﬁbrosis stage, is still
high, yet in the long run it is much less expensive than
treating only those with advanced ﬁbrosis, as indicated
by the ICERs which ranged from e8,775 to
e19,541.75/QALY gained. This model provides
important insight into extending access to DAAs to
patients in earlier ﬁbrosis stages, even those of
advanced age.
The cost-effectiveness of treating all HCV-infected
patients, regardless of disease severity, refers to a popu-
lation with a mean age of 59 years, which in part
reﬂects that of the general population of HCV patients
in Europe and populations in other parts of the world
that have similar epidemiologic characteristics (i.e.,
individuals infected many years previously through
blood transfusion or nosocomial transmission with his-
torical trends of high incidence of infection).(32-34)
Our results indicate that the wide use of DAA regi-
mens in Europe has a good cost-effectiveness proﬁle;
however, in different countries, the effects of the thera-
pies vary signiﬁcantly, and speciﬁc population-based
health policies are required.(35) The ICER that was
produced using the Italian and the European scenario
could be generalized to populations that are similar in
terms of age and liver-disease stage. In countries where
the epidemiology of HCV infection is quite different,
such as in the United States (excluding baby boomers),
the higher drug prices would obviously increase the
ICER. However, because the HCV-infected popula-
tion in the United States is younger than our popula-
tion, greater beneﬁts would result, which would
contribute to decreasing the ICER.
In this study, a probabilistic sensitivity analysis was
carried out by varying main model inputs (i.e., treat-
ment efﬁcacy, the utility of each health state, transi-
tions, and costs).(36) Speciﬁcally, for policy 1, cost-
effectiveness was conﬁrmed in 94%-97% of the 10,000
simulations, in that the ICERs remained considerably
below the accepted threshold, indicating substantial
health gains in this real-life cohort. These cost-
effectiveness results are supported by clinical data.
Treating only patients in advanced stages of ﬁbrosis is
a negative predictor of the SVR, and it does not
prevent the progression of liver disease or HCC devel-
opment in all patients, although the progression rate is
lower than that among untreated patients.(3,19-22,37)
Although the impact of comorbidities was not evalu-
ated, the comorbidity pattern could negatively inﬂu-
ence the long-term effectiveness and the mortality rate
not related to HCV following the “delayed” versus the
“universal” treatment. On the other hand, HCV-
related disease inﬂicts a huge economic and clinical
burden, also as a result of the infection’s extrahepatic
comorbidities, and early HCV eradication will reduce
these burdens.(38-40) Furthermore, although delaying
treatment is an attractive option for insurers, it fails to
take into account the clinical and economic beneﬁts of
early treatment in terms of prevention and quality of
life.(40,41) These additional clinical and prevention
rationales, coupled with the results of this study, fur-
ther support the notion that the reported cost-
effectiveness data could translate into additional clini-
cal and economic beneﬁts and strongly indicate the
necessity to move from the urgency to treat select
patients to access for all chronically infected patients.
The health of a human being is always cost-
effective. However, the sustainability of innovations is
a challenge for health systems, and a variety of strate-
gies need to be tested. Despite the very good cost-
effectiveness proﬁle obtained in this study, affordability
is one of the main factors that determine the prescrib-
ing of DAAs for all patients. Budget impact analyses
are required for each country in order to determine
how to afford the high initial investment, which in the
long run is cost-effective.
In the scenario analysis, we went beyond a cost-
effectiveness analysis, varying the price of treatment
regimens for different stages of ﬁbrosis. If the price
remains unvaried for patients with the severest disease
(i.e., those who are currently treated) yet is lowered for
less severe patients (patients who do not yet have access
to treatment), then treating HCV infection has a
much more favorable cost-effectiveness proﬁle and
could become cost-saving.
This study has several limits that could affect the
robustness of the model and the impact of the results.
Speciﬁcally, we considered only patients who were
aware of their HCV infection. In the base-case analy-
sis, we used single transition rates for all ages and gen-
ders. Fibrosis stage is classiﬁed according to
noninvasive measurement which, although widely
used, has limits in diagnostic accuracy, speciﬁcally with
regard to the deﬁnition of ﬁbrosis stages F3-F4. Using
the nonlinear progression of liver disease and a further
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exponential distribution in F3-F4 stages of liver ﬁbro-
sis, we could have at least partly avoided the possible
bias of “understaging” or “overstaging” of liver disease.
In addition, patients from F3-F4 to cirrhosis have pri-
oritized treatment, and modeling this assumption
could have better approximated the reality of priori-
tized patients.
The model does not distinguish patients on the basis
of alcohol consumption, metabolic syndrome, or
comorbidities, although these factors may affect treat-
ment outcomes and costs. These factors are more com-
mon in patients with ﬁbrosis stage higher than F3, and
their impact on the results might be minimal, given
that this group of patients was included in both treat-
ment scenarios. The costs of managing adverse effects
were not estimated; however, DAAs do not have
adverse effects that could signiﬁcantly impact the
model. Patients with severe liver disease could have
had more adverse effects following DAA treatment,
yet this group of patients was equally represented in
both scenarios. The regression of liver ﬁbrosis after
successful treatment was not taken into consideration,
whereas patients who do not reach SVR proceed
through the natural history of liver disease progression
without being retreated. These assumptions may have
led to the ICERs having been overestimated. The
reinfection rate was not considered, which could have
produced an underestimate in the ICER. Discontinua-
tion of therapy and retreatment were not considered,
which could have resulted in the costs having been
underestimated. On the other hand, the societal
impact of antiviral treatment has not been considered,
and the exclusion of societal costs from the analysis
may have led to our having underestimated the value
of the universal versus prioritized treatment. One
potential limit of this study concerns the differences in
the distribution of the population among ﬁbrosis stages
and therefore the potential QALY gain, which is asso-
ciated with the individuals’ health states. To limit the
effect of this possible bias in the ICER estimation, in
the multivariate sensitivity analysis, utilities as well as
transition probabilities were varied for the base-case
and for the European scenario analysis. Moreover, in
the latter analysis the original population was
resampled to better represent a population of infected
HCV patients in care who would not be necessarily
Italian.
In conclusion, at a base price of e15,000 for a DAA
regimen in Italy and at a mean European price of
e30,000, treating HCV infection at early stages of
ﬁbrosis appeared to improve health outcomes and to
be cost-effective. Cost-effectiveness increased signiﬁ-
cantly, becoming cost-saving when varying the price of
treatment regimens in early stages of ﬁbrosis. Speciﬁ-
cally, for the price levels that were lower than 75% of
the base price (e15,000) applied in patients with F0-
F2 ﬁbrosis stage, policy 1 (i.e., “universal treatment”)
became dominant (lower costs and greater beneﬁts in
terms of QALYs) compared to policy 2 (i.e.,
“prioritized treatment”).
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